Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00098397 Completed - Clinical trials for Stage IV Breast Cancer

FR901228 in Treating Patients With Metastatic Breast Cancer

Start date: February 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well FR901228 works in treating patients with metastatic breast cancer. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00097721 Completed - Breast Neoplasms Clinical Trials

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.

NCT ID: NCT00097487 Completed - Breast Cancer Clinical Trials

A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

Start date: November 30, 2000
Phase: N/A
Study type: Observational

This study is a Phase IV, prospective, nonrandomized, community-based study of clinical outcomes in patients with metastatic breast cancer treated with Herceptin and a taxane.

NCT ID: NCT00097383 Completed - Breast Cancer Clinical Trials

Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized Phase 2 portion of a study testing ALIMTA and epirubicin in combination for locally advanced or metastatic breast cancer. Epirubicin is a well-established drug for the therapy of breast cancer. Both ALIMTA and epirubicin have been combined with other drugs but they have not yet been combined with each other. It is expected that the patient will benefit from the different mechanisms of action of the two drugs.

NCT ID: NCT00097344 Terminated - Breast Neoplasms Clinical Trials

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

NCT ID: NCT00096668 Completed - Breast Cancer Clinical Trials

Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This is an open label study where each patient will receive TOCOSOL(R) Paclitaxel 120mg/m2 every week for first line treatment of metastatic breast cancer. Patients will be followed to determine the efficacy of treatment (as measured by objective response rate), and the safety associated with weekly administration of TOCOSOL Paclitaxel.

NCT ID: NCT00096434 Completed - Clinical trials for Stage IV Breast Cancer

Sorafenib in Treating Patients With Metastatic Breast Cancer

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with metastatic breast cancer. Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.

NCT ID: NCT00096369 Terminated - Breast Cancer Clinical Trials

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

Start date: February 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tamoxifen may be effective in preventing breast cancer. PURPOSE: This randomized phase II trial is studying tamoxifen to see how well it works compared to placebo in preventing breast cancer in women who are at increased risk for the disease.

NCT ID: NCT00096356 Completed - Breast Cancer Clinical Trials

Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer

CoQ10
Start date: August 27, 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Coenzyme Q10 is a vitamin that may be effective in relieving fatigue and depression in women who are undergoing chemotherapy for breast cancer. PURPOSE: This randomized clinical trial is studying how well coenzyme Q10 works in relieving treatment-related fatigue in women with breast cancer.

NCT ID: NCT00096343 Completed - Breast Cancer Clinical Trials

Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer

Start date: October 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed. Combining paclitaxel with carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin works in treating women who are undergoing surgery for newly diagnosed, locally advanced breast cancer.